---
figid: PMC3028978__cvq37001
figlink: /pmc/articles/PMC3028978/figure/CVQ370F1/
number: F1
caption: The classic arginine–nitric oxide synthase–nitric oxide pathway. This figure illustrates
  the ‘classic’ nitric oxide pathway and both cyclic guanosine monophosphate-dependent
  and -independent signalling. Furthermore, the figure highlights the multiple levels
  of this pathway that can be taken advantage of for therapeutic benefit. One strategy
  is to increase nitric oxide synthase substrate availability via l-arginine supplementation
  or arginase inhibitors. Alternative strategies are to increase nitric oxide synthase
  enzymes via gene or protein therapy as well as direct deliver of nitric oxide gas
  via inhalation or pharmacological donors. Additionally, therapeutics take advantage
  of cyclic guanosine monophosphate-dependent signalling including phosphodiesterase
  inhibitors, such as sildenafil, and the direct guanylate cyclase activators such
  as riociguat.
pmcid: PMC3028978
papertitle: 'Nitrite in pulmonary arterial hypertension: therapeutic avenues in the
  setting of dysregulated arginine/nitric oxide synthase signalling.'
reftext: Brian S. Zuckerbraun, et al. Cardiovasc Res. 2011 Feb 15;89(3):542-552.
pmc_ranked_result_index: '28755'
pathway_score: 0.9552239
filename: cvq37001.jpg
figtitle: Classic arginine–nitric oxide synthase–nitric oxide pathway
year: '2011'
organisms:
- Homo sapiens
ndex: 1e2dc681-ded8-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3028978__cvq37001.html
  '@type': Dataset
  description: The classic arginine–nitric oxide synthase–nitric oxide pathway. This
    figure illustrates the ‘classic’ nitric oxide pathway and both cyclic guanosine
    monophosphate-dependent and -independent signalling. Furthermore, the figure highlights
    the multiple levels of this pathway that can be taken advantage of for therapeutic
    benefit. One strategy is to increase nitric oxide synthase substrate availability
    via l-arginine supplementation or arginase inhibitors. Alternative strategies
    are to increase nitric oxide synthase enzymes via gene or protein therapy as well
    as direct deliver of nitric oxide gas via inhalation or pharmacological donors.
    Additionally, therapeutics take advantage of cyclic guanosine monophosphate-dependent
    signalling including phosphodiesterase inhibitors, such as sildenafil, and the
    direct guanylate cyclase activators such as riociguat.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - NOS3
  - PDE3A
  - PDE11A
  - PDE2A
  - PDE8A
  - PDE3B
  - PDE9A
  - PDE1A
  - NT5C2
  - PDE10A
  - NOS1
  - PDE6B
  - PDE1C
  - PDE4B
  - PDE7B
  - PDE6A
  - PDE7A
  - PDE1B
  - PDE4C
  - PDE4A
  - PDE6C
  - PDE4D
  - NOS2
  - SGCB
  - GC
  - PDE8B
  - Arginine
  - L-arginine
  - urea
genes:
- word: NOS
  symbol: NOS
  source: bioentities_symbol
  hgnc_symbol: NOS3
  entrez: '4846'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE3A
  entrez: '5139'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE11A
  entrez: '50940'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE2A
  entrez: '5138'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE8A
  entrez: '5151'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE3B
  entrez: '5140'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE9A
  entrez: '5152'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE1A
  entrez: '5136'
- word: GMP
  symbol: GMP
  source: hgnc_alias_symbol
  hgnc_symbol: NT5C2
  entrez: '22978'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE10A
  entrez: '10846'
- word: NOS
  symbol: NOS
  source: bioentities_symbol
  hgnc_symbol: NOS1
  entrez: '4842'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE6B
  entrez: '5158'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE1C
  entrez: '5137'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4B
  entrez: '5142'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE7B
  entrez: '27115'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE6A
  entrez: '5145'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE7A
  entrez: '5150'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE1B
  entrez: '5153'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4C
  entrez: '5143'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4A
  entrez: '5141'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE6C
  entrez: '5146'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE4D
  entrez: '5144'
- word: NOS
  symbol: NOS
  source: bioentities_symbol
  hgnc_symbol: NOS2
  entrez: '4843'
- word: SGC
  symbol: SGC
  source: hgnc_alias_symbol
  hgnc_symbol: SGCB
  entrez: '6443'
- word: GC
  symbol: GC
  source: hgnc_symbol
  hgnc_symbol: GC
  entrez: '2638'
- word: PDE
  symbol: PDE
  source: bioentities_symbol
  hgnc_symbol: PDE8B
  entrez: '8622'
chemicals:
- word: Arginine
  source: MESH
  identifier: D001120
- word: L-arginine
  source: MESH
  identifier: D001120
- word: urea
  source: MESH
  identifier: D014508
diseases: []
figid_alias: PMC3028978__F1
redirect_from: /figures/PMC3028978__F1
figtype: Figure
---
